India cracks down on manufacturers; Vivimed says FDA OK with API plant in Spain;

> India's Drugs Control Administration issued show cause notices to 23 drug manufacturers and seized drugs from two others while inspecting 25 facilities last month. Report

> India's Vivimed Labs says its API plant in Spain successfully passed an FDA inspection. Report

> Israel-based SciVac Therapeutics says it has resumed production of its hepatitis B vaccine at a plant in British Columbia, which it earlier stopped because some vials had been damaged during labeling. Release

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Mylan is the most recent drugmaker facing the FDA's ire over a tainted API that led to a global recall of "sartan"-based drugs last year.

Merck MSD's $1.2 billion production restructuring has fallen on a site in France, where more than 200 manufacturing and R&D jobs will be swept away.